Pipeline

Scipher is determined to get patients the right drugs from day one.

 

Through our platform, we are building PrismDx and PrismRx to develop the tools doctors, pharmaceutical companies, and patients need to reach that goal.

Diagnostics

 

PrismRA is a simple blood test that predicts response to anti-TNF therapies for patients with Rheumatoid Arthritis, so they are prescribed treatments that are more likely to work meaning they suffer less irreversible joint damage.

 

 

PrismUC is a test that predicts response to anti-TNF therapies for patients with Ulcerative Colitis, so they are prescribed treatments that are more likely to help them reach remission and control their symptoms.

Therapeutics 

Over the next 18 months we will be collaborating with pharmaceutical companies to explore 25 targets in ulcerative colitis.

The data generated from PrismDX clearly defines the need for new drugs for patients who do not respond to currently available therapies.